Showing 5251-5260 of 5960 results for "".
- Novel Topical AD Drug Shows Promise in Phase 2 Studyhttps://practicaldermatology.com/news/novel-ad-drug-shows-promise-in-phase-2-study/2458555/Medimetriks’ MM36 (previously known as OPA-15406) performed well in a Phase 2 trial for the treatment of mild-to-moderate atopic dermatitis, a new study in in Journal of the American Academy of Dermatology shows. The investigational t
- Congrats: Dr. Barbara Gilchrest Receives the 24th David Martin Carter Mentor Awardhttps://practicaldermatology.com/news/congrats-dr-barbara-gilchrest-receives-the-24th-david-martin-carter-mentor-award/2458556/Barbara A. Gilchrest, MD of Harvard Medical School and Massachusetts General Hospital in Boston received the David Martin Carter Mentor Award at the Annual Meeting of the Society for Investigative Dermatology in Scottsdale, Ariz. Dr. Gilchrest plus the recipients of The Researc
- AXIM Biotech Begins Clinical Trials With Cannabigerol for Psoriasis and Eczemahttps://practicaldermatology.com/news/axim-biotech-begins-clinical-trials-with-cannabigerol-for-psoriasis-and-eczema/2458562/AXIM Biotechnologies, Inc. launched human dermatological clinical trials based on its proprietary, patent-pending topical ointment formulation AX-1602 that includes the "stem cell cannabinoid" cannabigerol (CBG) and other cannabinoids. The two indications for AXIM's AX-1602 in human
- Dr. Brandt's Legacy Lives on with New Dr. Brandt® Skincare Advisory Boardhttps://practicaldermatology.com/news/dr-brandts-legacy-lives-on-with-new-dr-brandt-skincare-advisory-board/2458563/Dr. Brandt® Skincare is rolling out a new Advisory Board to elevate the brand and honor Dr. Brandt’s legacy of innovation in dermatology. Frederick Brandt died on April 5, 2015 in his home in Coconut Grove, Florida. The first
- Untreated Sleep Apnea Linked to Melanoma Aggressionhttps://practicaldermatology.com/news/untreated-sleep-apnea-linked-to-melanoma-aggressiveness/2458564/Untreated severe obstructive sleep apnea (OSA) is linked to increased aggressiveness of malignant cutaneous melanoma, according to research presented at the American Thoracic Society 2016 International Conference in San Francisco. The study involved 412 patients, average age 55.8, w
- Feet Get Skin Cancer Too, ACFAS Warnshttps://practicaldermatology.com/news/feet-get-skin-cancer-too-acfas-warns/2458565/Skin cancer of the foot is prevalent and can be fatal if not caught early, the American College of Foot and Ankle Surgeons (ACFAS) warns. While all types of skin cancer, including squamous cell and basal cell carcinoma, can be found
- Is Eli Lilly's Taltz the Next Blockbuster Drug for Psoriasis?https://practicaldermatology.com/news/is-eli-lillys-taltz-the-next-blockbuster-drug-for-psoriasis/2458569/Eli Lilly’s new psoriasis drug Taltz (ixekizumab) is set to generate sales in excess of $1 billion in the US and Europe by 2022 due to its efficacy and good safety profile, according to an analyst at GlobalData.
- Meet Alastin's Restore & Renew Anti-Aging Linehttps://practicaldermatology.com/news/meet-alastins-restore-renew-anti-aging-line/2458570/ALASTINTM Skincare, Inc., is rolling the newest addition to their portfolio -- the Restore & Renew Anti-Aging line. The line consists of four products: the Restorative Skin ComplexTM, the Restorative Eye Tre
- Dermira's Novel Facial Acne Treatment Passes Muster in Phase 2b Studyhttps://practicaldermatology.com/news/dermiras-drm01-performs-well-in-facial-acne-study/2458571/Dermira’s novel topical sebum inhibitor -- DRMO1 -- may put the brakes on facial acne, according to topline results from a Phase 2b dose-ranging study that is paving the way toward a Phase 3 Clinical Program. DRM01 is a novel, small molecul
- Skin Cancer Expert Perry Robins, MD Joins Emerald's Advisory Boardhttps://practicaldermatology.com/news/skin-cancer-expert-perry-robins-md-joins-emeralds-advisory-board/2458574/New York City dermatologist Perry Robins, MD has joined Emerald Medical Applications Corp.’s advisory board. Emerald, an Israeli-based company, is developing DermaCompare™, a proprietary artificial intelligence free app